At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
immediate-release tacrolimus +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients
In Brief
A Phase 2 clinical trial evaluating immediate-release tacrolimus and extended release tacrolimus for Kidney Transplant Failure and Rejection. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The primary objective is to compare the effect of treatment with an immediate-release tacrolimus to an extended-release tacrolimus (i.e., Envarsus® XR) immunosuppressive regimen on cognitive and motor function in kidney transplant recipients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplant Failure and Rejection
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMay 2018
Primary CompletionMar 2020
TodayJul 2026
First PostedFeb 19, 2018
Enrollment StartMay 8, 2018
Primary CompletionMar 31, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.4 years ago
Interventions
immediate-release tacrolimusdrug
Standard of care for transplant patients
extended release tacrolimusdrug
Experimental care